Anastrozole (DrugBank: Anastrozole)
3 diseases| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 78 | 下垂体前葉機能低下症 | 2 |
| 86 | 肺動脈性肺高血圧症 | 2 |
| 193 | プラダー・ウィリ症候群 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00133354 (ClinicalTrials.gov) | November 2001 | 19/8/2005 | Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys | Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency | Hypopituitarism | Drug: Arimidex (Anastrozole);Drug: Placebo;Drug: Growth Hormone | Nemours Children's Clinic | AstraZeneca;Genentech, Inc.;EMD Serono | Completed | 11 Years | 18 Years | Male | 53 | Phase 2;Phase 3 | United States |
| 2 | EUCTR2012-001183-30-Outside-EU/EEA (EUCTR) | 09/03/2012 | The purpose of this study is to see if Arimidex, an aromatase inhibitor, can delay bone fusion and increase predicted adult height in boys who are growth hormone deficient, in puberty, and who are taking growth hormone. | Double-blind trial investigating the safety and efficacy of the inhibitor anastrozole (arimidex) in delaying epiphyseal fusion and increasing height potential of adolescent males with growth hormone (GH) deficiency. | hypopituitarism MedDRA version: 14.1;Level: PT;Classification code 10021067;Term: Hypopituitarism;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Arimidex Product Name: Arimidex Product Code: ZD1033 INN or Proposed INN: anastrozole Other descriptive name: ANASTROZOLE | Nemours Children's Clinic | NULL | NA | Female: no Male: yes | 53 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03229499 (ClinicalTrials.gov) | December 7, 2017 | 18/7/2017 | Pulmonary Hypertension and Anastrozole Trial | Pulmonary Hypertension and Anastrozole Trial (PHANTOM) | Pulmonary Arterial Hypertension | Drug: Anastrozole;Drug: Placebo Oral Tablet | University of Pennsylvania | National Heart, Lung, and Blood Institute (NHLBI);Johns Hopkins University;University of Colorado, Denver;Rhode Island Hospital;Stanford University;Vanderbilt University;Washington University School of Medicine | Recruiting | 18 Years | N/A | All | 84 | Phase 2 | United States |
| 2 | NCT01545336 (ClinicalTrials.gov) | October 2012 | 29/2/2012 | Anastrozole in Patients With Pulmonary Arterial Hypertension | A Double-blind, Placebo-controlled Phase II Study of Anastrozole in Patients With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Drug: Anastrozole;Drug: Placebo | University of Pennsylvania | NULL | Completed | 18 Years | N/A | All | 18 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR1900027464 | 2019-12-01 | 2019-11-14 | Efficacy and safety of anastrozole combined with growth hormone in the treatment of Prader Willi syndrome in boys of large bone age | Efficacy and safety of anastrozole combined with growth hormone in the treatment of Prader Willi syndrome in boys of large bone age | Prader-Willi syndrome | control group:Single rhGH therapy;observation group:Anastrazole combined with growth hormone therapy; | Children's Hospital of Zhejiang University School of Medicine | NULL | Pending | Male | control group:20;observation group:20; | Phase 4 | China | ||
| 2 | NCT01520467 (ClinicalTrials.gov) | April 2012 | 25/1/2012 | Aromatase Inhibitor in Bone Maturation, Children With Silver Russell or Prader-Willi Syndrome | Efficacy and Tolerance of Treatment With an Aromatase Inhibitor (Anastrozole) to Limit the Progression of Bone Maturation Related to Pathological Adrenarche in Children With Silver-Russell or Prader-Willi Syndrome | Silver Russell Syndrome;Prader-Willi Syndrome | Drug: Anastrozole;Drug: Placebo | Assistance Publique - Hôpitaux de Paris | NULL | Active, not recruiting | 5 Years | 12 Years | Both | 27 | N/A | France |